GSTM1、P1基因多态对接受铂类药物辅助化疗的胃癌患者预后的影响

doi:10.3971/j.issn.1000-8578.2331

GSTM1、P1基因多态对接受铂类药物辅助化疗的胃癌患者预后的影响

Prognostic Impact of GSTM1 and GSTP1 Polymorphism on Gastric Cancer Patients Treated with Platinum-based Adjuvant Chemotherapy

摘要

摘要: 目的探讨GSTM1、GSTP1基因多态与胃癌对铂类药物辅助化疗预后的关系。方法确诊的胃癌患者84例,采用铂类药物为主的方案进行辅助化疗;采用聚合酶链反应-连接酶检测反应检测GSTM1和GSTP1 Ile105Val基因多态。结果84例胃癌患者中,43例(51.2%)携带GSTM1缺失基因型;GSTP1 Ile/Ile、Ile/Val和Val/Val分别占61.9%、28.6%和9.7%。携带GSTP1 Ile/Val和Val/Val基因型的胃癌患者无复发生存率和总生存率均显著高于携带Ile/Ile基因型患者(P<0.05)。多因素分析结果显示,GSTP1多态是影响患者复发的独立危险因素(P<0.05)。结论GSTP1 Ile105Val基因多态与接受铂类药物辅助化疗的胃癌患者的预后有关。

Abstract: Objective 　To investigate the association of GSTM1 and GSTP1 polymorphisms with the clini2 cal outcome of gast ric cancer patient s t reated with platinum2based adjuvant chemotherapy. Methods 　A total of 84 patient s with gast ric cancer were recruited. All patient s received platinum2based adjuvant chemotherapy. PCR2LDR (ligation detection reaction) method was used to detect genotypes of GSTM12 null and GSTP1 Ile105Val. Results 　Of the 84 patient s, the prevalence of the GSTM12null genotype was 51. 2 % and the f requencies of GSTP1 Ile/ Ile, Ile/ Val and Val/ Val genotype were 61. 9 %, 28. 6 % and 9. 7 %, respectively. The recurrence2f ree survival rate and overall survival rate in patient s with GSTP1 Ile/ Val and Val/ Val genotype were significantly higher than those in patient s with Ile/ Ile genotype ( P <0. 05) . Multivariable analysis showed that GSTP1 Ile/ Ile genotype was associated with shorter recur2 rence2f ree survival ( P < 0. 05) . Conclusion 　Polymorphism of GSTP1 Ile105Val may be a potential prog2 nostic factor in gast ric cancer patient s t reated with platinum2based adjuvant chemotherapy.

HTML全文

参考文献(0)

施引文献

资源附件(0)